ArticleOrphanet journal of rare diseases2023

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis.

Liu Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.